Eszopiclone (Lunesta) is likely the better choice for this patient with chronic insomnia on bupropion.
Both eszopiclone and suvorexant are reasonable options according to the 2017 AASM guidelines, which give weak recommendations for both agents in treating chronic insomnia 1. However, the evidence favors eszopiclone in this specific clinical context for several important reasons:
Why Eszopiclone Has the Edge
Broader Efficacy Profile
Eszopiclone treats both sleep onset AND sleep maintenance insomnia, while suvorexant is specifically recommended only for sleep maintenance insomnia 1. Since you haven't specified whether this patient struggles more with falling asleep versus staying asleep, eszopiclone's dual action provides more comprehensive coverage 1.
Superior Efficacy Data
The meta-analytic evidence shows eszopiclone demonstrates:
- 28-57 minutes increase in total sleep time (vs. only 10 minutes for suvorexant)
- 10-14 minutes reduction in wake after sleep onset (vs. 16-28 minutes for suvorexant)
- Moderate-to-large improvement in sleep quality (vs. not reported for suvorexant) 1
Longer Track Record
Eszopiclone has been studied in trials up to 6 months duration with demonstrated sustained efficacy 2. The evidence base is more robust, with proven effectiveness in 2-3 mg doses for adults 1.
Compatibility with Bupropion
Recent evidence specifically demonstrates that eszopiclone effectively treats insomnia in patients with major depressive disorder, improving both sleep and mood symptoms 3, 4. Since bupropion is an antidepressant, this suggests good compatibility in psychiatric populations.
Important Caveats About Suvorexant
While suvorexant is a newer orexin receptor antagonist with a different mechanism (blocking wakefulness rather than inducing sedation), the evidence is more limited:
- Smaller effect sizes on total sleep time 1
- Primarily effective for sleep maintenance, not sleep onset 1
- Safety signals detected for nervous system disorders in pharmacovigilance data 5
Practical Prescribing Approach
Start with eszopiclone 2-3 mg nightly 1:
- Use 2 mg initially, can increase to 3 mg if needed
- Take immediately before bedtime with at least 7-8 hours available for sleep
- Warn about unpleasant taste (18% incidence), dry mouth (4%), and somnolence (4%) 1
Monitor for:
- Improvement in sleep latency and total sleep time within 1-2 weeks
- Next-day residual sedation (more likely with 3 mg dose)
- Complex sleep behaviors (rare but serious FDA warning applies to all hypnotics)
If eszopiclone fails or is not tolerated, then consider suvorexant as a second-line option, particularly if the primary complaint is middle-of-the-night or early morning awakening 1.
Critical Safety Considerations
Both medications carry FDA warnings about complex sleep behaviors (sleep-driving, sleep-walking) 6. Counsel the patient explicitly about this risk and document the discussion. Use the lowest effective dose for the shortest duration needed.
Neither medication shows significant rebound insomnia upon discontinuation when used as directed 1, 7, which is an advantage over benzodiazepines.
The 2020 VA/DOD guidelines note insufficient evidence to definitively recommend for or against suvorexant 8, while eszopiclone maintains consistent support across multiple guidelines 1, 9.